New agents that are available to treat retinal vascular diseases (ie, faricimab and high-dose aflibercept) undisputedly extend durability versus conventional anti-vascular endothelial growth factor therapy. However, the characteristics of novel therapies range well beyond enhanced durability and differ substantially between the available agents. View world-renowned retina experts Dr Arshad Khanani and Dr Jennifer Lim as they debate and demonstrate the nuanced, evidence-based selection and dosing of new and emerging therapies across a wide spectrum of treatment-naïve and previously treated patients with neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/SIYLOO
- Start Date: 2024-11-27 06:00:00
- End Date: 2024-11-27 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: Genentech (Any division) - Amount: 96700.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest